Shionogi

The global antibiotic crisis: a 2020 perspective

July 2019 saw us take forward an anti- virulence programme from the Japanese pharma company Shionogi.

Shionogi launches thrombocytopenia treatment Mulpleo in the UK

New treatment option for patients with severe liver disease. The European subsidiary of Japanese pharma company Shionogi has announced the launch of its thrombocytopenia drug Mulpleo in the UK, offering a ... Shionogi's Mulpleo (lusutrombopag) is the

Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout

Pivotal mid-stage trial results due later this month. Japanese drugmaker Shionogi is making sure it is in pole position to acquire US biotech Tetra Therapeutics if its non-amyloid drug ... Shionogi chief executive Isao Teshirogi commented: “With the

Modest meeting sees only two drugs recommended by CHMP

The CHMP recommended a marketing authorisation of Japanese pharma company Shionogi’s antimicrobial drug Fetcroja (cefiderocol) for the treatment of infections caused by Gram-negative organisms in adults with limited treatment ... options. Shionogi’s

Antibiotic biotech Melinta files for bankruptcy

There are still players in the antibiotic and antimicrobial filed, however – Japanese pharma  Shionogi recently won FDA approval for its antimicrobial drug Fetroja, in the treatment of adults with complicated urinary

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]